We are focused on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours.
Macomics is an immuno-oncology company with world-leading expertise in macrophage biology
Our new website is coming soon
Latest News:
July 14th 2020 -Macomics, an immuno-oncology company, secures £3.2 million seed funding from Epidarex Capital & the Scottish Investment Bank
(Learn more)
Our Mission
Macomics are a UK-based drug discovery company working on first-in-class therapeutics that enhance the immune system by inhibiting the activities of tumour-associated macrophages (TAMs).
We're achieving this by employing world-class science, and novel candidate screening and validation technologies developed by our founders. All supported by an experienced team of executives and scientists.
Our Founders
Founded by world-leading TAM researcher Professor Jeffrey Pollard and Dr Luca Cassetta at the University of Edinburgh.
Latest News
Macomics, an immuno-oncology company, secures £3.2 million seed funding from Epidarex Capital & the Scottish Investment Bank
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, launches today with a £3.2 million seed financing round led by transatlantic VC Epidarex Capital, with the Scottish Investment Bank, the investment arm of Scottish Enterprise, also investing.
